Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRoFESS: Aggrenox vs Clopidogrel and Telmisartan vs Placebo in Stroke Prevention
NCT00153062Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2003
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 36
01
Overview
Phase 4, randomised, double-blind trial of dipyridamole and telmisartan in ischemic stroke (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only) at 4.4 years and Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only) at 4.4 years. Started Aug 2003; status: completed.
02
Drugs
dipyridamoletelmisartan
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00153062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00153062.